Cargando…
Phase II proof‐of‐concept study of atorvastatin in castration‐resistant prostate cancer
OBJECTIVES: To test for evidence of statin‐mediated effects in patients with castration‐resistant prostate cancer (CRPC) as post‐diagnosis use of statins in patients with prostate cancer is associated with favourable survival outcome. PATIENTS AND METHODS: The SPECTRE trial was a 6‐weeks‐long proof‐...
Autores principales: | Rushworth, Linda K., Loveridge, Carolyn, Salji, Mark, MacLeod, Martin, Mui, Ernest, Sumpton, David, Neilson, Matthew, Hedley, Ann, Alexander, Laura, McCartney, Elaine, Patel, Rachana, Wallace, Jan, Delles, Christian, Jones, Rob, Leung, Hing Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087532/ https://www.ncbi.nlm.nih.gov/pubmed/35844167 http://dx.doi.org/10.1111/bju.15851 |
Ejemplares similares
-
Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1
por: Patel, Rachana, et al.
Publicado: (2018) -
Multi-omics & pathway analysis identify potential roles for tumor N-acetyl aspartate accumulation in murine models of castration-resistant prostate cancer
por: Salji, Mark J., et al.
Publicado: (2022) -
Peri-prostatic Fat Volume Measurement as a Predictive Tool for Castration Resistance in Advanced Prostate Cancer
por: Salji, Mark, et al.
Publicado: (2018) -
Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression
por: Patel, Rachana, et al.
Publicado: (2022) -
PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer
por: Galbraith, Laura C. A., et al.
Publicado: (2021)